Toward engineering a human neoendothelium with circulating progenitor cells

Stem Cells

Volumn 28, Issue 2, 2010, Pages 318-328

  Allen, Josephine B ^a   Khan, Sadiya ^a   Lapidos, Karen A ^a   Ameer, Guillermo A ^a,b  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antithrombogenic; Elastomer; Endothelial progenitor cells; Fibrolytic

Indexed keywords

CD31 ANTIGEN; NITRIC OXIDE SYNTHASE; POLY(1,8 OCTANEDIOL CO CITRATE); POLYESTER; PROSTACYCLIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOT; CELL CULTURE; CELL DIFFERENTIATION; CELL POPULATION; CELL STRUCTURE; CIRCULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; PHENOTYPE; PROTEIN EXPRESSION; SHEAR STRESS; STAINING; STEM CELL; THROMBOCYTE ADHESION; TISSUE ENGINEERING;

ADULT; ANTIGENS, CD; ANTIGENS, CD31; CADHERINS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; STEM CELLS; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 77149164460     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.275     Document Type: Article

References (53)

1. Nerem RM, Ensley AE. The tissue engineering of blood vessels and the heart. Am J Transplant 2004;4:36-42.
2. Lemson MS, Tordoir JH, Daemen MJ et al. Intimal hyperplasia in vascular grafts. Eur J Vasc Endovasc Surg 2000;19:336-350.
3. Bordenave L, Remy-Zolghadri M, Fernandez P et al. Clinical performance of vascular grafts lined with endothelial cells. Endothelium 1999; 6:267-275.
4. Seifalian AM, Tiwari A, Hamilton G et al. Improving the clinical patency of prosthetic vascular and coronary bypass grafts: The role of seeding and tissue engineering. Artif Organs 2002;26:307-320.
5. Kaushal S, Amiel GE, Guleserian KJ et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001;7:1035-1040.
6. Aper T, Schmidt A, Duchrow M et al. Autologous blood vessels engineered from peripheral blood sample. Eur J Vasc Endovasc Surg 2007;33:33-39.
7. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85: 221-228.
8. Boyer M, Townsend LE, Vogel LM et al. Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000;31:181-189.
9. Lin Y, Weisdorf DJ, Solovey A et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105:71-77.
10. Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362-367.
11. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
12. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med 2005;56:79-101.
13. He H, Shirota T, Yasui H et al. Canine endothelial progenitor cell-lined hybrid vascular graft with nonthrombogenic potential. J Thorac Cardiovasc Surg 2003;126:455-464.
14. Kawamoto A, Tkebuchava T, Yamaguchi J et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003;107: 461-468.
15. Hinds MT, Ma M, Tran N et al. Potential of baboon endothelial progenitor cells for tissue engineered vascular grafts. J Biomed Mater Res A 2008;86:804-812.
16. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-353.
17. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis?Circulation 2004;109:II27-33.
18. Shirota T, He H, Yasui H et al. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing. Tissue Eng 2003;9:127-136.
19. Griese DP, Ehsan A, Melo LG et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: Implications for cell-based vascular therapy. Circulation 2003;108:2710-2715.
20. Yang J, Webb AR, Ameer GA. Novel citric acid-based biodegradable elastomers for tissue engineering. Adv Mater 2004;16:511-516.
21. Yang J, Webb AR, Pickerill SJ et al. Synthesis and evaluation of poly(diol citrate) biodegradable elastomers. Biomaterials 2006;27:1889-1898.
22. Kouretas PC, Hannan RL, Kapur NK et al. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: Role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol 1998;30:2669-2682.
23. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 2004;10:25-35.
24. Grunkemeier JM, Tsai WB, Horbett TA. Hemocompatibility of treated polystyrene substrates: contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J BiomedMater Res 1998;41:657-670.
25. Motlagh D, Allen J, Hoshi R et al. Hemocompatibility evaluation of poly(diol citrate) in vitro for vascular tissue engineering. J Biomed Mater Res A 2007;82:907-916.
26. Motlagh D, Yang J, Lui KY et al. Hemocompatibility evaluation of poly(glycerol-sebacate) in vitro for vascular tissue engineering. Biomaterials 2006;27:4315-4324.
27. Yang J, Motlagh D, Allen JB et al. Modulating ePTFE vascular graft host response via citric acid-based biodegradable elastomers. Adv Mater 2006;18:1493-1498.
28. Wang X, Lin P, Yao Q et al. Development of small-diameter vascular grafts. World J Surg 2007;31:682-689.
29. Green RM, Abbott WM, Matsumoto T et al. Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial. J Vasc Surg 2000;31:417-425.
30. Lim HJ, Nam HY, Lee BH et al. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol Prog 2007;23:693-697.
31. Laredo J, Xue L, Husak VA et al. Silyl-heparin adsorption improves the in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts. Am J Surg 2003;186:556-560.
32. Battaglia G, Tringale R, Monaca V. Retrospective comparison of a heparin bonded ePTFE graft and saphenous vein for infragenicular bypass: Implications for standard treatment protocol. The Journal of Cardiovascular Surgery (Torino) 2006;47:41-47.
33. Heise M, Schmidmaier G, Husmann I et al. PEG-hirudin/iloprost coating of small diameter ePTFE grafts effectively prevents pseudointima and intimal hyperplasia development. Eur J Vasc Endovasc Surg 2006;32:418-424.
34. Cagiannos C, Abul-Khoudoud OR, DeRijk W et al. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. J Vasc Surg 2005; 42:980-988.
35. Wong G, Li JM, Hendricks G et al. Inhibition of experimental neointimal hyperplasia by recombinant human thrombomodulin coated ePTFE stent grafts. J Vasc Surg 2008;47:608-615.
36. van der Zijpp YJ, Poot AA, Feijen J. Endothelialization of small-diameter vascular prostheses. Arch Physiol Biochem 2003;111:415-427.
37. Isenberg BC, Williams C, Tranquillo RT. Small-diameter artificial arteries engineered in vitro. Circ Res 2006;98:25-35.
38. Yang J, Motlagh D, Webb AR et al. Novel biphasic elastomeric scaffold for small-diameter blood vessel tissue engineering. Tissue Eng 2005;11:1876-1886.
39. Asher DM. Bovine sera used in the manufacture of biologicals: Current concerns and policies of the U.S. Food And Drug Administration Regarding The Transmissible Spongiform Encephalopathies. Dev Biol Stand 1999;99:41-44.
40. Michiels C. Endothelial cell functions. J Cell Physiol 2003;196: 430-443.
41. Laughlin MH, Turk JR, Schrage WG et al. Influence of coronary artery diameter on eNOS protein content. Am J Physiol Heart Circ Physiol 2003;284:H1307-1312.
42. Fann JI, Cahill PD, Mitchell RS et al. Regional variability of prostacyclin biosynthesis. Arteriosclerosis 1989;9:368-373.
43. Jen CJ, Huang TY, Chen HI et al. Regional differences in prostaglandin production rates among porcine intrathoracic vessels. Prostaglandins 1994;47:109-122.
44. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005;25:2470-2479.
45. Hrafnkelsdottir T, Ottosson P, Gudnason T et al. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 2004;44:300-304.
46. She M, McGuigan AP, Sefton MV. Tissue factor and thrombomodulin expression on endothelial cell-seeded collagen modules for tissue engineering. J Biomed Mater Res A 2007;80:497-504.
47. Ahern SM, Miyata T, Sadler JE. Regulation of human tissue factor expression by mRNA turnover. J Biol Chem 1993;268:2154-2159.
48. Bevilacqua MP, Pober JS, Majeau GR et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-623.
49. Allen J, Khan S, Serrano MC et al. Characterization of porcine circulating progenitor cells: Toward a functional endothelium. Tissue Eng Part A 2008;14:183-194.
50. Williams SK, Jarrell BE. Tissue-engineered vascular grafts. Nat Med 1996;2:32-34.
51. Sugawara Y, Miyata T, Sato O et al. Rapid postincubation endothelial retention by Dacron grafts. J Surg Res 1997;67:132-136.
52. Wang C, Zhang Q, Uchida S et al. A new vascular prosthesis coated with polyamino-acid urethane copolymer (PAU) to enhance endothelialization. J Biomed Mater Res 2002;62:315-322.
53. Kibbe MR, Martinez J, Popowich DA et al. Citric acid-based elastomers provide a biocompatible interface for vascular grafts. J Biomed Mater Res A. 2009.